PRT13722

Latest Post

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations Laurus Labs Q2 Results: Net Profit Surges 126% to ₹441 Crore as Revenue Grows 33%

Eli Lilly Prelude Breast Cancer Trial: PRT13722 Phase 1

October 14, 2026 Simone Lamb

Eli Lilly Prelude breast cancer trial: Lilly will supply two drugs for a Phase 1 study of PRT13722. Enrolment is due in Q4 2026; no human data yet.

You missed

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth

October 30, 2026 Simone Lamb

Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million

October 30, 2026 Simone Lamb

Healthcare Services

Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore

October 30, 2026 Simone Lamb

Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations

October 30, 2026 Simone Lamb